Get started
Author

Burcu Babaoğlan

Observed name: Burcu Babaoglan
ORCID: 0009-0007-7332-1613
Observed ORCID: 0009-0007-7332-1613
OpenAlex ID: A5002845385
Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al. · Clinical Cancer Research · 8
Supplementary Table S5 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Supplementary Table S8 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Supplementary Table S1 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Supplementary Table S6 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Table 2 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Supplementary Methods S1 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Table 3 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Supplementary Figure S2 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Figure 2 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Supplementary Table S9 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Supplementary Table S7 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Supplementary Figure S1 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Supplementary Table S3 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Figure 1 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Supplementary Table S2 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Table 1 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Figure 3 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Data from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Supplementary Table S4 from Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
2026 · Jonathan McConathy, Vadim S. Koshkin, et al.
Works count: 20
Citation count: 8
H-index: 1
I10-index:
Year
Topic
Type